Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : Spain's Rovi raises outlook thanks to Moderna vaccine contract

07/28/2021 | 02:37am EDT

MADRID, July 28 (Reuters) - Spanish pharmaceutical firm Rovi raised on Wednesday its profitability targets for this year thanks to its contract to manufacture the COVID-19 vaccine developed by U.S.-based Moderna.

Rovi said it expects its operating income to rose between 35% and 40% in 2021 from the previous year thanks to the Moderna vaccine, up from a previous target of between 20% and 30%.

Rovi, which currently bottles and finishes the Moderna vaccine for most markets outside the U.S., signed a contract in April with the U.S. company to also manufacture active ingredients for the vaccine.

"The massive vaccination programmes are ongoing all over the world and we are very proud to contribute to society with our work in this historic moment," the company said in a statement.

The vaccine business already boosted Rovi's operating income by 52% in the first half of the year from the same period a year ago to 290 million euros ($342.69 million), while its net profit jumped 72% to 51 million euros.

($1 = 0.8462 euros) (Reporting by Inti Landauro, editing by Louise Heavens)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
LABORATORIOS FARMACEUTICOS ROVI, S.A. 0.89% 56.5 Delayed Quote.47.76%
MODERNA, INC. 2.53% 434.04 Delayed Quote.305.22%
All news about MODERNA, INC.
05:57pMODERNA : Brazil and Argentina tapped to make mRNA vaccines in Latin America
RE
05:32pMODERNA : U.S. administers 386.8 mln doses of COVID-19 vaccines - CDC
RE
05:27pMODERNA : U.S. CDC Says Delivered 467,249,715 Doses Of Covid-19 Vaccine As Of Sept 21
RE
10:06aShangula Rages Against West's Vaccine Nationalism
AQ
09:55aJOHNSON & JOHNSON : Data Shows COVID-19 Booster Shots 94% Effective Against Moderate to Se..
MT
06:23aEUROPEAN MIDDAY BRIEFING : Stocks Rebound But -3-
DJ
06:04aNORTH AMERICAN MORNING BRIEFING : Markets Steady -2-
DJ
09/20MODERNA : U.S. administers 386.2 mln doses of COVID-19 vaccines - CDC
RE
09/20MODERNA : U.S. CDC Says Administered About 386.2 Million Doses Of Covid-19 Vaccine As Of S..
RE
09/20MODERNA : Regulators could OK Pfizer boosters for older Americans this week
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 348 M - -
Net income 2021 12 529 M - -
Net cash 2021 12 947 M - -
P/E ratio 2021 14,2x
Yield 2021 -
Capitalization 175 B 175 B -
EV / Sales 2021 7,97x
EV / Sales 2022 7,37x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 423,33 $
Average target price 306,23 $
Spread / Average Target -27,7%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.305.22%170 876
LONZA GROUP AG31.58%59 927
IQVIA HOLDINGS INC.43.03%48 510
CELLTRION, INC.-23.26%31 691
SEAGEN INC.-5.78%28 939
PHARMARON BEIJING CO., LTD.83.56%25 783